Still’s disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:02:51 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Still’s disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of MAS825 in Children and Adults with Still’s Disease to Test How Well It Works and How Safe It Is https://clinicaltrials.eu/trial/a-study-of-mas825-in-children-and-adults-with-stills-disease-to-test-how-well-it-works-and-how-safe-it-is/ Thu, 30 Apr 2026 13:08:16 +0000 https://clinicaltrials.eu/trial/a-study-of-mas825-in-children-and-adults-with-stills-disease-to-test-how-well-it-works-and-how-safe-it-is/ This study examines Still’s disease, a rare inflammatory condition that causes fever, rash, and joint pain. The condition can affect both children and adults, and it involves inflammation throughout the body that can lead to various symptoms including swelling of the joints and organs. The study will test a medicine called MAS825, which is a laboratory-made protein designed to block certain substances in the body that cause inflammation. Participants will also receive glucocorticoids, which are medications commonly used to reduce inflammation and are part of the standard treatment for this condition. The purpose of the study is to see how well MAS825 works in reducing disease activity in people with Still’s disease.

During the study, participants will receive MAS825 through an injection into a vein, under the skin, or into a muscle, along with their glucocorticoid treatment. The study will look at whether the treatment helps control the disease and whether it allows participants to reduce the amount of glucocorticoids they need to take. The treatment period can last for several years, during which participants will be monitored regularly to check how they are responding to the medicine.

Throughout the study, doctors will assess various aspects of the participants’ health, including changes in disease activity, physical function, and any side effects that may occur. Safety will be monitored through regular checks of vital signs, heart function using an ECG, and blood tests. The study will also track whether participants experience any unwanted effects from the treatment and whether the disease becomes inactive while taking lower doses of glucocorticoids.

]]> A study to evaluate the long-term safety of apremilast in children with oral ulcers from Behçet’s disease or juvenile psoriatic arthritis https://clinicaltrials.eu/trial/a-study-to-evaluate-the-long-term-safety-of-apremilast-in-children-with-oral-ulcers-from-behcet-s-disease-or-juvenile-psoriatic-arthritis/ Wed, 29 Apr 2026 15:08:59 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-long-term-safety-of-apremilast-in-children-with-oral-ulcers-from-behcet-s-disease-or-juvenile-psoriatic-arthritis/ This study is being conducted to evaluate the long-term safety of apremilast in children and young people. The research focuses on individuals living with Behçet’s disease, a long-term condition that causes inflammation throughout the body, or Juvenile Psoriatic Arthritis, a type of chronic joint inflammation that begins in childhood. In both conditions, the study specifically looks at those experiencing oral ulcers, which are painful sores located inside the mouth.

Participants in this study will take apremilast as an oral medication, which can be provided in the form of a film coated tablet or an oral solution. This is an open-label study, meaning that both the researchers and the participants will know which medication is being used. The study is a long-term extension, meaning it follows individuals who have previously participated in other research studies involving this same medication.

]]> Study on the Effectiveness and Safety of Deucravacitinib for Children and Teens with Juvenile Psoriatic Arthritis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-deucravacitinib-for-children-and-teens-with-juvenile-psoriatic-arthritis/ Wed, 29 Apr 2026 15:03:59 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-deucravacitinib-for-children-and-teens-with-juvenile-psoriatic-arthritis/ This clinical trial is focused on studying a condition called Juvenile Psoriatic Arthritis (JPsA), which affects children and teenagers. JPsA is a type of arthritis that not only causes joint pain and swelling but also involves skin problems similar to psoriasis, such as red, scaly patches. The trial will test a medication called deucravacitinib, also known by its code name BMS-986165. This medication is taken as a film-coated tablet and is being compared to a placebo to see if it can effectively manage the symptoms of JPsA in young participants.

The purpose of the study is to determine if deucravacitinib is more effective than a placebo in treating JPsA in children and adolescents aged 5 to 18. Participants will take the medication or placebo orally over a period of time, and researchers will monitor how long it takes for the first flare-up of the disease to occur. The study will also assess how much the disease improves, how many participants experience a reduction in symptoms, and how well the medication is tolerated, including its taste and ease of swallowing.

Throughout the study, researchers will keep track of any side effects and monitor the overall safety of deucravacitinib. They will also evaluate the amount of the medication in the body and its impact on the disease. The trial aims to provide valuable information on the effectiveness and safety of deucravacitinib for managing Juvenile Psoriatic Arthritis in young patients.

]]> Study on Anakinra for Children with Systemic Juvenile Idiopathic Arthritis https://clinicaltrials.eu/trial/study-on-anakinra-for-children-with-systemic-juvenile-idiopathic-arthritis/ Wed, 29 Apr 2026 15:02:30 +0000 https://clinicaltrials.eu/trial/study-on-anakinra-for-children-with-systemic-juvenile-idiopathic-arthritis/ This clinical trial is focused on studying a condition known as Systemic Juvenile Idiopathic Arthritis (sJIA), which is a type of autoimmune disorder affecting the joints. The treatment being investigated is a medication called anakinra, which is administered as a solution for injection. Anakinra is a type of protein that helps to block certain substances in the body that can cause inflammation and joint damage.

The purpose of this study is to explore a new strategy for using anakinra in children with sJIA. The study aims to determine if using a specific marker in the blood, called IL-18, can help guide the treatment process. This approach may help reduce the number of injections needed to keep the disease inactive during the first year of treatment. The study will involve an initial phase where patients receive anakinra, followed by a phase where the treatment is gradually reduced and stopped, depending on the patient’s response.

Throughout the study, researchers will monitor the number of injections required, the number of patients who achieve disease remission without medication, and any potential side effects. The goal is to find a more efficient way to manage sJIA, potentially reducing the treatment burden for patients while maintaining effective disease control.

]]> Study on the Safety and Effectiveness of Baricitinib and Tocilizumab for Children with Systemic Juvenile Idiopathic Arthritis https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-baricitinib-and-tocilizumab-for-children-with-systemic-juvenile-idiopathic-arthritis/ Wed, 29 Apr 2026 14:56:53 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-baricitinib-and-tocilizumab-for-children-with-systemic-juvenile-idiopathic-arthritis/ This clinical trial is focused on studying a condition known as Systemic Juvenile Idiopathic Arthritis (sJIA), which is a type of arthritis that affects children. The study aims to evaluate the safety and effectiveness of a medication called Baricitinib in children aged 1 to less than 18 years who have this condition. Baricitinib is a medication that comes in different forms, including film-coated tablets and oral suspension, and is taken by mouth. Another medication involved in the study is Tocilizumab, which is given as a solution for injection under the skin. The study also includes a placebo, which is a substance with no active medication, to compare the effects of the treatments.

The purpose of the study is to assess how well Baricitinib works in treating children with sJIA. Participants in the study will receive either Baricitinib, Tocilizumab, or a placebo. The study will monitor the participants over a period to see how their condition responds to the treatment. The main goal is to see if the participants achieve a certain level of improvement in their symptoms by week 12 of the study.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the medication affects their condition. The study is designed to provide valuable insights into the treatment of sJIA in children, potentially leading to better management of this condition in the future.

]]> Study of apremilast compared to placebo in children aged 5-17 years with juvenile psoriatic arthritis https://clinicaltrials.eu/trial/study-on-apremilast-for-children-aged-5-17-with-juvenile-psoriatic-arthritis/ Wed, 29 Apr 2026 14:47:57 +0000 https://clinicaltrials.eu/trial/study-on-apremilast-for-children-aged-5-17-with-juvenile-psoriatic-arthritis-2/ This study focuses on Juvenile Psoriatic Arthritis, a condition that causes joint inflammation in children and is often accompanied by a skin condition called psoriasis. The research examines the effectiveness of a medication called Apremilast, which will be compared to placebo in children aged 5 to less than 18 years old. The purpose of this study is to determine if Apremilast can help treat the symptoms of Juvenile Psoriatic Arthritis in young patients.

During the study, participants will receive either Apremilast (known as AMG 407) or placebo in the form of tablets or oral solution. The medication or placebo will be taken by mouth. The treatment period will last for 52 weeks, with the main assessment of the medication’s effectiveness occurring at week 16.

The study will monitor several aspects of the disease, including joint pain, inflammation, and overall disease activity. For participants who also have psoriasis affecting their skin, the improvement in skin symptoms will also be evaluated. The medication will be provided in different strengths, including 10 mg, 20 mg, and 30 mg tablets, as well as a liquid form containing 5 mg/mL.

]]>